Mobile App for Cancer

(ROSA App Trial)

This trial tests a new mobile app, the Mobile Symptom Monitoring and Alert App, designed to help manage symptoms for people receiving chemotherapy. The app uses real-time data from a Fitbit and patient-reported symptoms to suggest when to contact the care team. It aims to improve symptom management, quality of life, and communication with healthcare providers. Suitable candidates for this trial are those undergoing chemotherapy for any type of solid tumor cancer, have at least two cycles remaining, and use a compatible smartphone. Participants must complete daily symptom ratings and wear a Fitbit for 90 days. As an unphased trial, this study offers the opportunity to contribute to innovative research that could enhance cancer care for future patients.

The trial information does not specify whether you need to stop taking your current medications. It seems focused on using a mobile app to monitor symptoms during chemotherapy, so you likely won't need to change your medication routine.

Research has shown that mobile apps for cancer patients are generally safe and easy to use. These apps assist patients in reporting symptoms and managing treatment more effectively. Studies have found that these apps can help patients adhere to their treatment plans.

One study found that daily symptom reporting through mobile apps provides an easy way for patients to share their feelings. This simplicity means patients can use these apps without added stress. The information collected helps healthcare teams better understand and address issues patients face during chemotherapy.

The Mobile Symptom Monitoring and Alert App is unique because it leverages digital technology to track symptoms and vital signs in real-time, offering a more personalized approach to cancer care. Unlike traditional methods that rely on periodic doctor visits or patient self-reporting, this app allows for continuous monitoring via a smartphone, increasing the accuracy and timeliness of symptom management. Additionally, the integration with a Fitbit device provides comprehensive data on physical activity, heart rate, and other vital metrics, which can help in better understanding and addressing chemotherapy-related side effects. Researchers are excited about this approach because it has the potential to enhance patient engagement and outcomes by providing immediate feedback and alerts, leading to more proactive and precise interventions.

Research shows that mobile apps can help cancer patients manage their symptoms effectively. In this trial, participants will use the Mobile Symptom Monitoring and Alert App to track their symptoms daily for 90 days. Studies have found that such apps assist patients in tracking their symptoms and help them stick to their treatment plans. For example, one study discovered that using a mobile app to track symptoms during chemotherapy was both practical and helpful, making it easier for patients to report symptoms and communicate with their care teams. Another study highlighted that apps like the ChemoPro Application effectively improve symptom monitoring. These findings suggest that using a mobile app during chemotherapy can enhance symptom management and improve the overall quality of life for patients.¹³⁶⁷⁸